Target Name: OR10AG1
NCBI ID: G282770
Review Report on OR10AG1 Target / Biomarker Content of Review Report on OR10AG1 Target / Biomarker
OR10AG1
Other Name(s): Olfactory receptor family 10 subfamily AG member 1 | olfactory receptor OR11-160 | Olfactory receptor OR11-160 | O10AG_HUMAN | OR11-160 | Olfactory receptor 10AG1 | olfactory receptor family 10 subfamily AG member 1

OR10AG1: A Potential Drug Target and Biomarker for Olfactory Receptor Family 10 Subfamily AG Member 1

Smell is a crucial sense that enables us to identify and remember various objects, emotions, and dangers. Olfactory receptor family 10 subfamily AG member 1 (OR10AG1), also known as GPR117, is a G protein-coupled receptor that plays a key role in mediating the sense of smell. OR10AG1 is expressed in the vomiting neurons of the olfactory system, which are responsible for transmitting smell information from the nose to the brain. Therefore, alterations in OR10AG1 function have been implicated in various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and chronic insomnia.

Drugs that target OR10AG1 have the potential to treat various neurological and psychiatric disorders. For example, olfactory receptor antagonists have been shown to improve sensory function in patients with Alzheimer's disease, while inhibitors of OR10AG1 have been shown to reduce anxiety and improve sleep quality in patients with insomnia. Additionally, several compounds have been shown to modulate OR10AG1 function in a specific context, such as the use of aromatherapy, which is a form of therapy that uses essential oils to promote physical and psychological well-being.

In recent years, the study of OR10AG1 has also been motivated by the potential of this receptor as a drug target for treating psychiatric disorders. Activation of OR10AG1 has been shown to increase activity in dopamine-dependent circuits, which are involved in mood regulation. Additionally , OR10AG1 has been shown to interact with other neurogenic receptors, such as the GPR55 receptor, which is involved in pain modulation. Therefore, targeting OR10AG1 with small molecules or other compounds that modulate its function could provide new insights into the treatment of psychiatric disorders.

In addition to its potential therapeutic applications, OR10AG1 is also a potential biomarker for various neurological disorders. The sense of smell is a critical factor in the diagnosis of disorders that affect the nervous system, such as Alzheimer's disease and Parkinson's disease. Therefore, changes in OR10AG1 function may provide valuable information for the diagnosis and prognosis of these disorders. Additionally, the use of Olfactory Receptor antagonists may be a useful diagnostic tool for these disorders, as changes in the function of OR10AG1 can often be detected by behavioral tests that measure the sense of smell.

In conclusion, OR10AG1 is a G protein-coupled receptor that plays a critical role in mediating the sense of smell. Its function is closely linked to various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and insomnia. The use of Olfactory receptor antagonists has been shown to improve sensory function in patients with these disorders, and the potential of OR10AG1 as a drug target and biomarker for these disorders makes it an attractive area of 鈥嬧?媟esearch. Further studies are needed to fully understand the function of OR10AG1 and its potential as a therapeutic target.

Protein Name: Olfactory Receptor Family 10 Subfamily AG Member 1

Functions: Odorant receptor

The "OR10AG1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about OR10AG1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

OR10AK1P | OR10C1 | OR10D1P | OR10D3 | OR10D4P | OR10G2 | OR10G3 | OR10G4 | OR10G7 | OR10G8 | OR10G9 | OR10H1 | OR10H2 | OR10H3 | OR10H4 | OR10H5 | OR10J1 | OR10J2P | OR10J3 | OR10J5 | OR10K1 | OR10K2 | OR10P1 | OR10Q1 | OR10R2 | OR10S1 | OR10T2 | OR10V1 | OR10W1 | OR10X1 | OR10Z1 | OR11A1 | OR11G2 | OR11H1 | OR11H12 | OR11H13P | OR11H2 | OR11H5P | OR11H6 | OR11H7 | OR11J2P | OR11J5P | OR11K2P | OR11L1 | OR11M1P | OR12D2 | OR12D3 | OR13A1 | OR13C2 | OR13C3 | OR13C4 | OR13C5 | OR13C8 | OR13C9 | OR13D1 | OR13F1 | OR13G1 | OR13H1 | OR13J1 | OR13Z2P | OR14A16 | OR14A2 | OR14C36 | OR14I1 | OR14J1 | OR14L1P | OR1A1 | OR1A2 | OR1B1 | OR1C1 | OR1D2 | OR1D4 | OR1D5 | OR1E1 | OR1E2 | OR1E3 | OR1F1 | OR1F2P | OR1G1 | OR1I1 | OR1J1 | OR1J2 | OR1J4 | OR1K1 | OR1L1 | OR1L3 | OR1L4 | OR1L6 | OR1L8 | OR1M1 | OR1N1 | OR1N2 | OR1P1 | OR1Q1 | OR1S1 | OR1S2 | OR2A1 | OR2A1-AS1 | OR2A12 | OR2A14